A phase II non randomized study evaluating the role of Androgen Receptors as Targets for therapy of pre-treated post-menopausal patients with ER/PgR-negative/AR-positive or ER and/or PgR-positive/AR-positive metastatic breast cancer
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Anastrozole (Primary) ; Exemestane (Primary) ; Letrozole (Primary) ; Prasterone (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
- Acronyms ARTT
- 29 Sep 2016 Biomarkers information updated
- 30 Apr 2013 New trial record